Ann: Quarterly Activity Report and Appendix 4C, page-4

Actually they did indicate a softening of the bedding sector last quarter [see below for an extract**].

Also their business is still cyclical which means quarters won't be even. You may see them lower against the last quarter but they are actually up 19% on the same period last year. So quarterly and YTD sales remain higher (39% YTD) than the equivalent periods last year. Also margin remains strong at >40% which I like.

Looks like the Body armour segment is gaining broader adoption with new customers coming on board (and this is global), but also PCM and biocool gaining new customers as well.
Plus they have launched FR sock which I think should gain broad adoption and bring in some big dollars - this really will be the best, healthiest and safest product on the market - frankly a law should be passed for universal adoption by all mattress suppliers - but still I expect wide adoption in the days ahead.


** From the December 2021 quarterly
Looking forward to 2H FY2022, the Company expects the 1H FY2022 positive trend for improving revenue and EBITDA to continue. This will be driven by new revenue streams which are beginning in 2H FY2022 as new customers adopt Biocool™ and Eclipsys™ products. The broader bedding market has softened beyond seasonality which is attributed to a number of factors including Omicron and supply chain issues. Orders from these new customers (that have commenced in January) mitigate this near-term impact.